Search Medical Condition
Please enter condition
Please choose location from dropdown

L'Hospitalet del Llobregat, Spain Clinical Trials

A listing of L'Hospitalet del Llobregat, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (1049) clinical trials

A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours

This is a two part Phase I/Ib, open-label, non-randomized and multi-center, dose escalation study with a 3+3 design (Part 1) and an expansion cohort at the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) (Part 2). If MTD is not reached in Part 1, RP2D will be determined after completion ...

Phase

0.0 miles

Learn More »

Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia

This is an observational, non-interventional study that will include two cohorts of patients with schizophrenia who initiated maintenance treatment during a schizophrenia-related hospitalisation or during the immediate three months after hospital discharge: patients who initiated maintenance treatment with AOM and patients who initiated maintenance treatment with any daily oral atypical ...

Phase N/A

0.0 miles

Learn More »

A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

This is an open-label, randomized active control study of BGB-3111 plus obinutuzumab versus obinutuzumab alone in subjects with relapsed or refractory follicular lymphoma. Randomization is 2:1 and subjects will be stratified by the number of prior lines of therapy (2 - 3 vs > 3) and rituximab-refractory status. The study ...

Phase

0.0 miles

Learn More »

Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis

Routine antibiotics for the intravenous and oral prophylaxis of colorectal surgery will be used. Experimental group: Patients undergoing elective colorectal surgery that involves, colonic resection. The antibiotic prophylaxis in this group will be composed of: An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) and metronidazole (250mg / ...

Phase

0.0 miles

Learn More »

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Phase II/III, prospective, multicenter, randomized (1:1), double-blind study to evaluate the efficacy and tolerability of axitinib in patients diagnosed with advanced G1-G2 neuroendocrine tumors (WHO 2010) of nonpancreatic origin that have presented documented disease progression in the 12 months prior to entering the study. In the first part of the ...

Phase

0.0 miles

Learn More »

Safety Profile of Idelalisib in Patients With Refractory Follicular Lymphoma

The primary objective of this study is to assess the overall safety profile of idelalisib monotherapy in patients with refractory follicular lymphoma (FL).

Phase N/A

0.0 miles

Learn More »

Atezolizumab Trial in Endometrial Cancer - AtTEnd

Atezolizumab is an engineered humanised monoclonal immunoglobulin G1 antibody that binds selectively to PD-L1 and prevents its interaction with PD-1 and B7-1. In May 2016 atezolizumab was approved by the FDA for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following any platinum-containing chemotherapy, ...

Phase

0.0 miles

Learn More »

Pembrolizumab in Combination With Doxorubicin in Advanced Recurrent or Metastatic Endometrial Cancer

This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.

Phase

0.0 miles

Learn More »

REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia

Phase I-II multi-site, exploratory, interventional, unmasked, non-randomized, single arm clinical trial. A single drug will be administered in four different, increasing doses to four consecutive cohorts. The first phase of the study will focus on determining the most effective and tolerated dose of the study drug. The second phase will ...

Phase

0.0 miles

Learn More »

SELIBORDARA: Selinexor Bortezomib and Daratumumab in Multiple Myeloma

This is a Phase 2, single-arm, open, non-randomized, multicenter study of the SINE compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab. Sixty-two patients with R/R MM who meet eligibility criteria and have none of the exclusion criteria will be enrolled to receive SVDd until either disease progression ...

Phase

0.0 miles

Learn More »